Logo image of SLGC

SOMALOGIC INC (SLGC) Stock Fundamental Analysis

NASDAQ:SLGC - Nasdaq - US83444K1051 - Common Stock - Currency: USD

2.1  -0.1 (-4.55%)

After market: 2 -0.1 (-4.76%)

Fundamental Rating

3

SLGC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. While SLGC has a great health rating, there are worries on its profitability. SLGC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLGC had negative earnings in the past year.
SLGC had a negative operating cash flow in the past year.
SLGC Yearly Net Income VS EBIT VS OCF VS FCFSLGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

SLGC has a worse Return On Assets (-23.08%) than 68.85% of its industry peers.
SLGC has a Return On Equity of -26.25%. This is comparable to the rest of the industry: SLGC outperforms 40.98% of its industry peers.
Industry RankSector Rank
ROA -23.08%
ROE -26.25%
ROIC N/A
ROA(3y)-17.05%
ROA(5y)N/A
ROE(3y)-20.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLGC Yearly ROA, ROE, ROICSLGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

Looking at the Gross Margin, with a value of 41.14%, SLGC is in line with its industry, outperforming 44.26% of the companies in the same industry.
In the last couple of years the Gross Margin of SLGC has grown nicely.
The Profit Margin and Operating Margin are not available for SLGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 41.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.12%
GM growth 5YN/A
SLGC Yearly Profit, Operating, Gross MarginsSLGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 50 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

SLGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SLGC has more shares outstanding
There is no outstanding debt for SLGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLGC Yearly Shares OutstandingSLGC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 50M 100M 150M
SLGC Yearly Total Debt VS Total AssetsSLGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

SLGC has an Altman-Z score of 2.03. This is not the best score and indicates that SLGC is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of SLGC (2.03) is comparable to the rest of the industry.
SLGC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.03
ROIC/WACCN/A
WACC12.33%
SLGC Yearly LT Debt VS Equity VS FCFSLGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 17.77 indicates that SLGC has no problem at all paying its short term obligations.
SLGC has a Current ratio of 17.77. This is amongst the best in the industry. SLGC outperforms 95.08% of its industry peers.
SLGC has a Quick Ratio of 17.27. This indicates that SLGC is financially healthy and has no problem in meeting its short term obligations.
SLGC has a Quick ratio of 17.27. This is amongst the best in the industry. SLGC outperforms 95.08% of its industry peers.
Industry RankSector Rank
Current Ratio 17.77
Quick Ratio 17.27
SLGC Yearly Current Assets VS Current LiabilitesSLGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

SLGC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
SLGC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.73%.
SLGC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 44.77% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-19.73%
Revenue growth 3Y44.77%
Revenue growth 5YN/A
Sales Q2Q%-47.13%

3.2 Future

Based on estimates for the next years, SLGC will show a small growth in Earnings Per Share. The EPS will grow by 3.80% on average per year.
Based on estimates for the next years, SLGC will show a quite strong growth in Revenue. The Revenue will grow by 11.84% on average per year.
EPS Next Y-2.43%
EPS Next 2Y3.89%
EPS Next 3Y4.51%
EPS Next 5Y3.8%
Revenue Next Year-12.14%
Revenue Next 2Y1.69%
Revenue Next 3Y7.5%
Revenue Next 5Y11.84%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SLGC Yearly Revenue VS EstimatesSLGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
SLGC Yearly EPS VS EstimatesSLGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLGC Price Earnings VS Forward Price EarningsSLGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLGC Per share dataSLGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.89%
EPS Next 3Y4.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOMALOGIC INC

NASDAQ:SLGC (1/5/2024, 8:26:28 PM)

After market: 2 -0.1 (-4.76%)

2.1

-0.1 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-08 2023-11-08/amc
Earnings (Next)03-26 2024-03-26/amc
Inst Owners0.05%
Inst Owner Change0%
Ins Owners0.46%
Ins Owner Change0%
Market Cap396.23M
Analysts80
Price Target4.01 (90.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.28%
Min EPS beat(2)17.77%
Max EPS beat(2)30.8%
EPS beat(4)3
Avg EPS beat(4)10.01%
Min EPS beat(4)-21.38%
Max EPS beat(4)30.8%
EPS beat(8)7
Avg EPS beat(8)20.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.4%
Min Revenue beat(2)1.23%
Max Revenue beat(2)5.58%
Revenue beat(4)4
Avg Revenue beat(4)7.3%
Min Revenue beat(4)1.23%
Max Revenue beat(4)11.55%
Revenue beat(8)6
Avg Revenue beat(8)11.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.46%
EPS NY rev (1m)0%
EPS NY rev (3m)11.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.85
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.43
BVpS2.63
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.08%
ROE -26.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 41.14%
FCFM N/A
ROA(3y)-17.05%
ROA(5y)N/A
ROE(3y)-20.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.12%
GM growth 5YN/A
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.2%
Cap/Sales 4.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.77
Quick Ratio 17.27
Altman-Z 2.03
F-Score3
WACC12.33%
ROIC/WACCN/A
Cap/Depr(3y)139.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.22%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-2.43%
EPS Next 2Y3.89%
EPS Next 3Y4.51%
EPS Next 5Y3.8%
Revenue 1Y (TTM)-19.73%
Revenue growth 3Y44.77%
Revenue growth 5YN/A
Sales Q2Q%-47.13%
Revenue Next Year-12.14%
Revenue Next 2Y1.69%
Revenue Next 3Y7.5%
Revenue Next 5Y11.84%
EBIT growth 1Y-0.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.1%
EBIT Next 3Y14.46%
EBIT Next 5Y7.07%
FCF growth 1Y-359.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-444.14%
OCF growth 3YN/A
OCF growth 5YN/A